Celgene Will Discontinue Phase III MAINSAIL® Trial in Castrate-Resistant Prostate Cancer

Celgene International Sàrl, a subsidiary of Celgene Corporation,

announced that based on the recommendation from the Data Monitoring Committee it will discontinue its pivotal double-blinded Phase III MAINSAIL trial that was designed to evaluate the efficacy and safety of docetaxel and prednisone with or without lenalidomide in patients with castrate-resistant prostate cancer.